Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Servier
Eli Lilly and Company
Turning Point Therapeutics, Inc.
Sichuan Enray Pharmaceutical Sciences Company
Arvinas Inc.
Eli Lilly and Company
Sensei Biotherapeutics, Inc.
ModeX Therapeutics, An OPKO Health Company
TransThera Sciences (Nanjing), Inc.
Hoffmann-La Roche
Xynomic Pharmaceuticals, Inc.
Salubris Biotherapeutics Inc
NantCell, Inc.
Turning Point Therapeutics, Inc.
TransThera Sciences (Nanjing), Inc.
Genmab
Kineta Inc.
Institut Bergonié
Dana-Farber Cancer Institute
Lumos Pharma